Thomas W. Flaig
University of Colorado Cancer Center · 406 works · 23,612 citations · h-index 53
Top works
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
- Bladder Cancer, Version 3.2024
- A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
- Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018